119 results on '"He, Qiaojun"'
Search Results
2. Macrophage senescence in health and diseases
- Author
-
Wang, Longling, Hong, Wenxiang, Zhu, Hong, He, Qiaojun, Yang, Bo, Wang, Jiajia, and Weng, Qinjie
- Published
- 2024
- Full Text
- View/download PDF
3. Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis
- Author
-
Ge, Fujing, Zeng, Chenming, Wang, Jiaer, Liu, Xiangning, Zheng, Churun, Zhang, Hongyu, Yang, Liu, Yang, Bo, Zhu, Hong, and He, Qiaojun
- Published
- 2024
- Full Text
- View/download PDF
4. Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
- Author
-
Zhang, Wenxin, Pan, Xiaohui, Xu, Yanjun, Guo, Hongjie, Zheng, Mingming, Chen, Xi, Wu, Honghai, Luan, Fengming, He, Qiaojun, Ding, Ling, and Yang, Bo
- Published
- 2023
- Full Text
- View/download PDF
5. Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
- Author
-
Xie, Yaochen, Zhou, Qian, He, Qiaojun, Wang, Xiaoyi, and Wang, Jincheng
- Published
- 2023
- Full Text
- View/download PDF
6. Dasatinib causes keratinocyte apoptosis via inhibiting high mobility group Box 1-mediated mitophagy
- Author
-
Gao, Zizheng, Hu, Yuhuai, Fu, Huangxi, Jiang, Feng, Yan, Hao, Yang, Xiaochun, Yang, Bo, He, Qiaojun, Luo, Peihua, and Xu, Zhifei
- Published
- 2023
- Full Text
- View/download PDF
7. Deubiquitination complex platform: A plausible mechanism for regulating the substrate specificity of deubiquitinating enzymes
- Author
-
Fang, Yi-Zheng, Jiang, Li, He, Qiaojun, Cao, Ji, and Yang, Bo
- Published
- 2023
- Full Text
- View/download PDF
8. Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
- Author
-
Li, Kailin, You, Jieqiong, Wu, Qian, Meng, Wen, He, Qiaojun, Yang, Bo, Zhu, Chengliang, and Cao, Ji
- Published
- 2021
- Full Text
- View/download PDF
9. Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib
- Author
-
Du, Jiangxia, Li, Guanqun, Jiang, Liyu, Zhang, Xiaochen, Xu, Zhifei, Yan, Hao, Zhou, Ziye, He, Qiaojun, Yang, Xiaochun, and Luo, Peihua
- Published
- 2021
- Full Text
- View/download PDF
10. Keratinocytes apoptosis contributes to crizotinib induced-erythroderma
- Author
-
Hu, Yuhuai, Zhang, Xiaochen, Zhao, Ziying, Chen, Xueqin, Zhou, Ziye, Yang, Xiaochun, Yang, Bo, He, Qiaojun, and Luo, Peihua
- Published
- 2020
- Full Text
- View/download PDF
11. High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity
- Author
-
Xu, Zhifei, Jin, Ying, Yan, Hao, Gao, Zizheng, Xu, Bo, Yang, Bo, He, Qiaojun, Shi, Qiang, and Luo, Peihua
- Published
- 2018
- Full Text
- View/download PDF
12. HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy
- Author
-
Luo, Peihua, Zhu, Yi, Chen, Min, Yan, Hao, Yang, Bo, Yang, Xiaochun, and He, Qiaojun
- Published
- 2018
- Full Text
- View/download PDF
13. The involvement of M2 macrophage polarization inhibition in fenretinide-mediated chemopreventive effects on colon cancer
- Author
-
Dong, Rong, Gong, Yanling, Meng, Wen, Yuan, Meng, Zhu, Hong, Ying, Meidan, He, Qiaojun, Cao, Ji, and Yang, Bo
- Published
- 2017
- Full Text
- View/download PDF
14. DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan
- Author
-
Cao, Ji, Lin, Guanyu, Gong, Yanling, Pan, Peichen, Ma, Yaxi, Huang, Ping, Ying, Meidan, Hou, Tingjun, He, Qiaojun, and Yang, Bo
- Published
- 2016
- Full Text
- View/download PDF
15. Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress
- Author
-
Shen, Zeren, Shao, Jinjin, Dai, Jiabin, Lin, Yuchen, Yang, Xiaochun, Ma, Jian, He, Qiaojun, Yang, Bo, Yao, Ke, and Luo, Peihua
- Published
- 2016
- Full Text
- View/download PDF
16. AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells.
- Author
-
Bing, Shaowei, Xiang, Senfeng, Xia, Zhimei, Wang, Yilong, Guan, Zhonghai, Che, Jinxin, Xu, Aixiao, Dong, Xiaowu, Cao, Ji, Yang, Bo, Wang, Jinhu, He, Qiaojun, and Ying, Meidan
- Subjects
NEUROBLASTOMA ,CELL differentiation ,PROTEIN kinase B ,CHEMICAL libraries ,PROTEIN kinases - Abstract
While neuroblastoma accounts for 15% of childhood tumor-related deaths, treatments against neuroblastoma remain scarce and mainly consist of cytotoxic chemotherapeutic drugs. Currently, maintenance therapy of differentiation induction is the standard of care for neuroblastoma patients in clinical, especially high-risk patients. However, differentiation therapy is not used as a first-line treatment for neuroblastoma due to low efficacy, unclear mechanism, and few drug options. Through compound library screening, we accidently found the potential differentiation-inducing effect of AKT inhibitor Hu7691. The protein kinase B (AKT) pathway is an important signaling pathway for regulating tumorigenesis and neural differentiation, yet the relation between the AKT pathway and neuroblastoma differentiation remains unclear. Here, we reveal the anti-proliferation and neurogenesis effect of Hu7691 on multiple neuroblastoma cell lines. Further evidence including neurites outgrowth, cell cycle arrest, and differentiation mRNA marker clarified the differentiation-inducing effect of Hu7691. Meanwhile, with the introduction of other AKT inhibitors, it is now clear that multiple AKT inhibitors can induce neuroblastoma differentiation. Furthermore, silencing AKT was found to have the effect of inducing neuroblastoma differentiation. Finally, confirmation of the therapeutic effects of Hu7691 is dependent on inducing differentiation in vivo , suggesting that Hu7691 is a potential molecule against neuroblastoma. Through this study, we not only define the key role of AKT in the progression of neuroblastoma differentiation but also provide potential drugs and key targets for the application of differentiation therapies for neuroblastoma clinically. This study not only defines the key role of AKT in the progression of neuroblastoma differentiation but also provides potential drugs and key targets for the application of differentiation therapies for neuroblastoma clinically. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. The impact of lipids on the cancer–immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy.
- Author
-
Zheng, Mingming, Zhang, Wenxin, Chen, Xi, Guo, Hongjie, Wu, Honghai, Xu, Yanjun, He, Qiaojun, Ding, Ling, and Yang, Bo
- Subjects
LIPID metabolism ,ANTIGEN presenting cells ,LIPIDS ,MAJOR histocompatibility complex ,ANTIGEN presentation - Abstract
Lipids have been found to modulate tumor biology, including proliferation, survival, and metastasis. With the new understanding of tumor immune escape that has developed in recent years, the influence of lipids on the cancer–immunity cycle has also been gradually discovered. First, regarding antigen presentation, cholesterol prevents tumor antigens from being identified by antigen presenting cells. Fatty acids reduce the expression of major histocompatibility complex class I and costimulatory factors in dendritic cells, impairing antigen presentation to T cells. Prostaglandin E2 (PGE2) reduce the accumulation of tumor-infiltrating dendritic cells. Regarding T-cell priming and activation, cholesterol destroys the structure of the T-cell receptor and reduces immunodetection. In contrast, cholesterol also promotes T-cell receptor clustering and relative signal transduction. PGE2 represses T-cell proliferation. Finally, regarding T-cell killing of cancer cells, PGE2 and cholesterol weaken granule-dependent cytotoxicity. Moreover, fatty acids, cholesterol, and PGE2 can improve the activity of immunosuppressive cells, increase the expression of immune checkpoints and promote the secretion of immunosuppressive cytokines. Given the regulatory role of lipids in the cancer–immunity cycle, drugs that modulate fatty acids, cholesterol and PGE2 have been envisioned as effective way in restoring antitumor immunity and synergizing with immunotherapy. These strategies have been studied in both preclinical and clinical studies. Lipids regulate cancer immunity cycle by affecting antigen presentation, T-cell priming and activation and T-cell killing of tumor, which in turn promotes immune surveillance escape. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. BZYX, a novel acetylcholinesterase inhibitor, significantly improved chemicals-induced learning and memory impairments on rodents and protected PC12 cells from apoptosis induced by hydrogen peroxide
- Author
-
Zhang, Jing, Zhu, Difeng, Sheng, Rong, Wu, Honghai, Hu, Yongzhou, Wang, Feng, Cai, Tianyu, Yang, Bo, and He, Qiaojun
- Published
- 2009
- Full Text
- View/download PDF
19. Q39, a novel synthetic Quinoxaline 1,4-Di- N-oxide compound with anti-cancer activity in hypoxia
- Author
-
Weng, Qinjie, Wang, Duoduo, Guo, Peng, Fang, Liang, Hu, Yongzhou, He, Qiaojun, and Yang, Bo
- Published
- 2008
- Full Text
- View/download PDF
20. Corrigendum to “5-Fluorouracil causes severe CNS demyelination by disruption of TCF7L2/HDAC1/HDAC2 complex in adolescent mice” [Toxicology 325 (2014) 144–150]
- Author
-
Weng, Qinjie, Tan, Biqin, Wang, Jiajia, Wang, Jing, Zhou, Hui, Shi, Jing, He, QiaoJun, and Yang, Bo
- Published
- 2020
- Full Text
- View/download PDF
21. The regulatory and modulatory roles of TRP family channels in malignant tumors and relevant therapeutic strategies.
- Author
-
Zhong, Tiecheng, Zhang, Wenxin, Guo, Hongjie, Pan, Xiaohui, Chen, Xi, He, Qiaojun, Yang, Bo, and Ding, Ling
- Subjects
TRP channels ,FAMILY roles ,CALCIUM channels ,REACTIVE oxygen species ,MULTIDRUG resistance - Abstract
Transient receptor potential (TRP) channels are one primary type of calcium (Ca
2+ ) permeable channels, and those relevant transmembrane and intracellular TRP channels were previously thought to be mainly associated with the regulation of cardiovascular and neuronal systems. Nowadays, however, accumulating evidence shows that those TRP channels are also responsible for tumorigenesis and progression, inducing tumor invasion and metastasis. However, the overall underlying mechanisms and possible signaling transduction pathways that TRP channels in malignant tumors might still remain elusive. Therefore, in this review, we focus on the linkage between TRP channels and the significant characteristics of tumors such as multi-drug resistance (MDR), metastasis, apoptosis, proliferation, immune surveillance evasion, and the alterations of relevant tumor micro-environment. Moreover, we also have discussed the expression of relevant TRP channels in various forms of cancer and the relevant inhibitors' efficacy. The chemo-sensitivity of the anti-cancer drugs of various acting mechanisms and the potential clinical applications are also presented. Furthermore, it would be enlightening to provide possible novel therapeutic approaches to counteract malignant tumors regarding the intervention of calcium channels of this type. Transient receptor potential (TRP) channels are sensitive to various stimuli such as hypoxia, stretch and reactive oxygen species. We elucidate the mechanisms between TRP channels and cancer progression and propose potential approaches of tumor therapy. [Display omitted] [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
22. Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells.
- Author
-
Shao, Xuejing, Chen, Yingqian, Wang, Wei, Du, Wenxin, Zhang, Xingya, Cai, Minyi, Bing, Shaowei, Cao, Ji, Xu, Xiaojun, Yang, Bo, He, Qiaojun, and Ying, Meidan
- Subjects
ACUTE promyelocytic leukemia ,ARSENIC trioxide ,RETINOIC acid receptors ,TRETINOIN ,CHROMOSOMAL translocation ,SMALL molecules ,OVARIAN tumors - Abstract
In most acute promyelocytic leukemia (APL) cells, promyelocytic leukemia (PML) fuses to retinoic acid receptor α (RAR α) due to chromosomal translocation, thus generating PML/RAR α oncoprotein, which is a relatively stable oncoprotein for degradation in APL. Elucidating the mechanism regulating the stability of PML/RAR α may help to degrade PML/RAR α and eradicate APL cells. Here, we describe a deubiquitinase (DUB)-involved regulatory mechanism for the maintenance of PML/RAR α stability and develop a novel pharmacological approach to degrading PML/RAR α by inhibiting DUB. We utilized a DUB siRNA library to identify the ovarian tumor protease (OTU) family member deubiquitinase YOD1 as a critical DUB of PML/RAR α. Suppression of YOD1 promoted the degradation of PML/RAR α , thus inhibiting APL cells and prolonging the survival time of APL cell-bearing mice. Subsequent phenotypic screening of small molecules allowed us to identify ubiquitin isopeptidase inhibitor I (G5) as the first YOD1 pharmacological inhibitor. As expected, G5 notably degraded PML/RAR α protein and eradicated APL, particularly drug-resistant APL cells. Importantly, G5 also showed a strong killing effect on primary patient-derived APL blasts. Overall, our study not only reveals the DUB-involved regulatory mechanism on PML/RAR α stability and validates YOD1 as a potential therapeutic target for APL, but also identifies G5 as a YOD1 inhibitor and a promising candidate for APL, particularly drug-resistant APL treatment. Deubiquitinase YOD1 is responsible for cleaving polyubiquitin chains for PML/RAR α to escape from ubiquitin-dependent degradation. G5 as the first YOD1 inhibitor degrades PML/RAR α to suppress drug-resistant APL progression. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. WSB1 regulates c-Myc expression through β-catenin signaling and forms a feedforward circuit.
- Author
-
Gao, Xiaomeng, You, Jieqiong, Gong, Yanling, Yuan, Meng, Zhu, Haiying, Fang, Liang, Zhu, Hong, Ying, Meidan, He, Qiaojun, Yang, Bo, and Cao, Ji
- Subjects
UBIQUITIN ligases ,TRANSCRIPTION factors ,RNA sequencing ,CARCINOGENESIS - Abstract
The dysregulation of transcription factors is widely associated with tumorigenesis. As the most well-defined transcription factor in multiple types of cancer, c-Myc can transform cells by transactivating various downstream genes. Given that there is no effective way to directly inhibit c-Myc, c-Myc targeting strategies hold great potential for cancer therapy. In this study, we found that WSB1, which has a highly positive correlation with c-Myc in 10 cancer cell lines and clinical samples, is a direct target gene of c-Myc, and can positively regulate c-Myc expression, which forms a feedforward circuit promoting cancer development. RNA sequencing results from Bel-7402 cells confirmed that WSB1 promoted c-Myc expression through the β -catenin pathway. Mechanistically, WSB1 affected β -catenin destruction complex-PPP2CA assembly and E3 ubiquitin ligase adaptor β -TRCP recruitment, which inhibited the ubiquitination of β -catenin and transactivated c-Myc. Of interest, the effect of WSB1 on c-Myc was independent of its E3 ligase activity. Moreover, overexpressing WSB1 in the Bel-7402 xenograft model could further strengthen the tumor-driven effect of c-Myc overexpression. Thus, our findings revealed a novel mechanism involved in tumorigenesis in which the WSB1/c-Myc feedforward circuit played an essential role, highlighting a potential c-Myc intervention strategy in cancer treatment. WSB1 promoted the expression of c-Myc through WNT/ β -catenin pathway, which enhanced the cancer promoting effect induced by c-Myc in a E3 ligase activity independent manner. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis.
- Author
-
Wang, Jincheng, Hu, Kaili, Cai, Xuanyan, Yang, Bo, He, Qiaojun, Wang, Jiajia, and Weng, Qinjie
- Subjects
PI3K/AKT pathway ,IDIOPATHIC pulmonary fibrosis ,FIBROSIS ,PULMONARY fibrosis ,PHOSPHATIDYLINOSITOL 3-kinases ,CELLULAR signal transduction ,NATURAL products - Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic interstitial pneumonia with unknown causes. The incidence rate increases year by year and the prognosis is poor without cure. Recently, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT) signaling pathway can be considered as a master regulator for IPF. The contribution of the PI3K/AKT in fibrotic processes is increasingly prominent, with PI3K/AKT inhibitors currently under clinical evaluation in IPF. Therefore, PI3K/AKT represents a critical signaling node during fibrogenesis with potential implications for the development of novel anti-fibrotic strategies. This review epitomizes the progress that is being made in understanding the complex interpretation of the cause of IPF, and demonstrates that PI3K/AKT can directly participate to the greatest extent in the formation of IPF or cooperate with other pathways to promote the development of fibrosis. We further summarize promising PI3K/AKT inhibitors with IPF treatment benefits, including inhibitors in clinical trials and pre-clinical studies and natural products, and discuss how these inhibitors mitigate fibrotic progression to explore possible potential agents, which will help to develop effective treatment strategies for IPF in the near future. PI3K/AKT signaling participates in the formation of idiopathic pulmonary fibrosis (IPF), and some promising PI3K/AKT inhibitors already show IPF treatment benefits, making targeting PI3K/AKT a novel anti-fibrotic strategy. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.
- Author
-
Qian, Meijia, Yan, Fangjie, Wang, Weihua, Du, Jiamin, Yuan, Tao, Wu, Ruilin, Zhao, Chenxi, Wang, Jiao, Lu, Jiabin, Zhang, Bo, Lin, Nengming, Dong, Xin, Dai, Xiaoyang, Dong, Xiaowu, Yang, Bo, Zhu, Hong, and He, Qiaojun
- Subjects
CHOLANGIOCARCINOMA ,DEUBIQUITINATING enzymes ,PROTEIN stability - Abstract
Cholangiocarcinoma (CCA) has emerged as an intractable cancer with scanty therapeutic regimens. The aberrant activation of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are reported to be common in CCA patients. However, the underpinning mechanism remains poorly understood. Deubiquitinase (DUB) is regarded as a main orchestrator in maintaining protein homeostasis. Here, we identified Josephin domain-containing protein 2 (JOSD2) as an essential DUB of YAP/TAZ that sustained the protein level through cleavage of polyubiquitin chains in a deubiquitinase activity-dependent manner. The depletion of JOSD2 promoted YAP/TAZ proteasomal degradation and significantly impeded CCA proliferation in vitro and in vivo. Further analysis has highlighted the positive correlation between JOSD2 and YAP abundance in CCA patient samples. Collectively, this study uncovers the regulatory effects of JOSD2 on YAP/TAZ protein stabilities and profiles its contribution in CCA malignant progression, which may provide a potential intervention target for YAP/TAZ-related CCA patients. JOSD2, a deubiquitinating enzyme, increases YAP/TAZ abundance and reinforces their signaling through the cleavage of polyubiquitin chains, observably contributing to cholangiocarcinoma progression. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Phosphorylation regulates cullin-based ubiquitination in tumorigenesis.
- Author
-
Chen, Yifan, Shao, Xuejing, Cao, Ji, Zhu, Hong, Yang, Bo, He, Qiaojun, and Ying, Meidan
- Subjects
UBIQUITINATION ,BIOLOGICAL crosstalk ,NEOPLASTIC cell transformation ,PHOSPHORYLATION ,THERAPEUTICS ,TUMOR suppressor proteins - Abstract
Cullin-RING ligases (CRLs) recognize and interact with substrates for ubiquitination and degradation, and can be targeted for disease treatment when the abnormal expression of substrates involves pathologic processes. Phosphorylation, either of substrates or receptors of CRLs, can alter their interaction. Phosphorylation-dependent ubiquitination and proteasome degradation influence various cellular processes and can contribute to the occurrence of various diseases, most often tumorigenesis. These processes have the potential to be used for tumor intervention through the regulation of the activities of related kinases, along with the regulation of the stability of specific oncoproteins and tumor suppressors. This review describes the mechanisms and biological functions of crosstalk between phosphorylation and ubiquitination, and most importantly its influence on tumorigenesis, to provide new directions and strategies for tumor therapy. This review summarizes the crosstalk between phosphorylation and ubiquitination in different biological processes and diseases, mainly cancers, and highlights the therapeutic potential of the crosstalk in tumor treatments. Image 1 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression.
- Author
-
Yuan, Meng, Chen, Xiaobing, Sun, Yitang, Jiang, Li, Xia, Zhongni, Ye, Kaixiong, Jiang, Hong, Yang, Bo, Ying, Meidan, Cao, Ji, and He, Qiaojun
- Subjects
OVARIAN cancer ,CANCER invasiveness ,PROTEIN stability ,POST-translational modification ,OVARIES - Abstract
The membrane protein claudin-3 (CLDN3) is critical for the formation and maintenance of tight junction and its high expression has been implicated in dictating malignant progression in various cancers. However, the post-translational modification of CLDN3 and its biological function remains poorly understood. Here, we report that CLDN3 is positively correlated with ovarian cancer progression both in vitro and in vivo. Of interest, CLDN3 undergoes S -palmitoylation on three juxtamembrane cysteine residues, which contribute to the accurate plasma membrane localization and protein stability of CLDN3. Moreover, the deprivation of S -palmitoylation in CLDN3 significantly abolishes its tumorigenic promotion effect in ovarian cancer cells. By utilizing the co-immunoprecipitation assay, we further identify ZDHHC12 as a CLDN3-targating palmitoyltransferase from 23 ZDHHC family proteins. Furthermore, the knockdown of ZDHHC12 also significantly inhibits CLDN3 accurate membrane localization, protein stability and ovarian cancer cells tumorigenesis. Thus, our work reveals S -palmitoylation as a novel regulatory mechanism that modulates CLDN3 function, which implies that targeting ZDHHC12-mediated CLDN3 S -palmitoylation might be a potential strategy for ovarian cancer therapy. ZDHHC12-mediated S -palmitoylation promotes the cell membrane localization of CLDN3 and maintains its stability in ovarian cancer cells, contributing to the oncoprotein function of CLDN3. When ZDHHC12 was knocked down, CLDN3 was insufficiently S -palmitoylated leading to intracellular distribution and preference to degradation, which berried tumor growth. Image 1 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
- Author
-
Zhao, Chenxi, Zeng, Chenming, Ye, Song, Dai, Xiaoyang, He, Qiaojun, Yang, Bo, and Zhu, Hong
- Subjects
HYPOXIA-inducible factors ,HYPOXEMIA ,TRANSCRIPTION factors ,CANCER ,PROTEINS - Abstract
Hypoxia is a common feature of solid tumors. As transcription factors, hypoxia-inducible factors (HIFs) are the master regulators of the hypoxic microenvironment; their target genes function in tumorigenesis and tumor development. Intriguingly, both yes-associated protein (YAP) and its paralog transcriptional coactivator with a PDZ-binding motif (TAZ) play fundamental roles in the malignant progression of hypoxic tumors. As downstream effectors of the mammalian Hippo pathway, YAP and/or TAZ (YAP/TAZ) are phosphorylated and sequestered in the cytoplasm by the large tumor suppressor kinase 1/2 (LATS1/2)-MOB kinase activator 1 (MOB1) complex, which restricts the transcriptional activity of YAP/TAZ. However, dephosphorylated YAP/TAZ have the ability to translocate to the nucleus where they induce transcription of target genes, most of which are closely related to cancer. Herein we review the tumor-related signaling crosstalk between YAP/TAZ and hypoxia, describe current agents and therapeutic strategies targeting the hypoxia–YAP/TAZ axis, and highlight questions that might have a potential impact in the future. This review summarizes the tumor-related signaling crosstalk between YAP/TAZ and hypoxia, describes current agents and therapeutic strategies targeting the hypoxia–YAP/TAZ axis, and highlights questions that might have a potential impact in the future. Image 1 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
- Author
-
Chen, Xi, Pan, Xiaohui, Zhang, Wenxin, Guo, Hongjie, Cheng, Shuyuan, He, Qiaojun, Yang, Bo, and Ding, Ling
- Subjects
TUMOR antigens ,EPIGENETICS ,IMMUNOTHERAPY ,IMMUNE response ,IMMUNE system - Abstract
Immunotherapy strategies targeting the programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) pathway in clinical treatments have achieved remarkable success in treating multiple types of cancer. However, owing to the heterogeneity of tumors and individual immune systems, PD-L1/PD-1 blockade still shows slow response rates in controlling malignancies in many patients. Accumulating evidence has shown that an effective response to anti-PD-L1/anti-PD-1 therapy requires establishing an integrated immune cycle. Damage in any step of the immune cycle is one of the most important causes of immunotherapy failure. Impairments in the immune cycle can be restored by epigenetic modification, including reprogramming the environment of tumor-associated immunity, eliciting an immune response by increasing the presentation of tumor antigens, and by regulating T cell trafficking and reactivation. Thus, a rational combination of PD-L1/PD-1 blockade and epigenetic agents may offer great potential to retrain the immune system and to improve clinical outcomes of checkpoint blockade therapy. An effective response to anti-PD-L1/anti-PD-1 therapy requires the establishment of an integrated immune cycle. Impaired immune cycle can be restored by epigenetic modification, including reprogramming the tumor-associated immunity and eliciting an immune response. Epigenetic combination therapies may be optimally integrated to enhance the response rates of PD-L1/PD-1 blockade. Image 1 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. Author correction to 'Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA' [Acta Pharmaceutica Sinica B 13 (2023) 2585–2600].
- Author
-
Zhang, Wenxin, Pan, Xiaohui, Xu, Yanjun, Guo, Hongjie, Zheng, Mingming, Chen, Xi, Wu, Honghai, Luan, Fengming, He, Qiaojun, Ding, Ling, and Yang, Bo
- Subjects
MESSENGER RNA - Published
- 2023
- Full Text
- View/download PDF
31. Corrigendum to “HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy” [Toxicol. Lett. 292 (2018) 115–121]
- Author
-
Luo, Peihua, Zhu, Yi, Chen, Min, Yan, Hao, Yang, Bo, Yang, Xiaochun, and He, Qiaojun
- Published
- 2020
- Full Text
- View/download PDF
32. Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells.
- Author
-
Chang, Linlin, Hu, Yan, Fu, Yingying, Zhou, Tianyi, You, Jun, Du, Jiamin, Zheng, Lin, Cao, Ji, Ying, Meidan, Dai, Xiaoyang, Su, Dan, He, Qiaojun, Zhu, Hong, and Yang, Bo
- Subjects
OVARIAN cancer ,DRUG resistance in cancer cells ,METASTASIS ,CANCER cells ,OVARIES - Abstract
Metastasis-associated drug resistance accounts for high mortality in ovarian cancer and remains to be a major barrier for effective treatment. In this study, SKOV3/T4, a metastatic subpopulation of ovarian cancer SKOV3 cells, was enriched to explore potential interventions against metastatic-associated drug resistance. Quantitative genomic and functional analyses were performed and found that slug was significantly increased in the SKOV3/T4 subpopulation and contributed to the high resistance of SKOV3/T4. Further studies showed that slug activated c-Met in a ligand-independent manner due to elevated levels of fibronectin and provoked integrin α V function, which was confirmed by the significant correlation of slug and p-Met levels in 121 ovarian cancer patient samples. Intriguingly, c-Met inhibitor(s) exhibited greatly enhanced anti-cancer effects in slug-positive ovarian cancer models both in vitro and in vivo. Additionally, IHC analyses revealed that slug levels were highly correlated with reduced survival of ovarian cancer patients. Taken together, this study not only uncovers the critical roles of slug in drug resistance in ovarian cancer but also highlights a promising therapeutic strategy by targeting the noncanonical activation of c-Met in slug-positive ovarian cancer patients with poor prognosis. In order to overcome chemotherapy resistance in metastatic ovarian cancer patients, we enriched a metastatic subpopulation of SKOV3 cells to explore the mechanisms underlying metastatic-associated drug resistance. Quantitative genomic and functional analyses uncover the critical roles of slug in metastatic-associated drug resistance, which can be overcome by c-Met inhibitor(s) both in vitro and in vivo. The finding also presents a new exciting opportunity to overcome metastatic-associated drug resistance for ovarian cancer patients by targeting c-Met signaling, particularly those patients harboring high expression levels of Slug and poor prognosis. fx1 [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Deubiquitinating enzymes: Promising targets for drug resistance.
- Author
-
Ge, Fujing, Li, Yuekang, Yuan, Tao, Wu, Yulian, He, Qiaojun, Yang, Bo, and Zhu, Hong
- Subjects
- *
DEUBIQUITINATING enzymes , *DRUG resistance , *DRUG resistance in cancer cells , *DRUG target , *COMBINATION drug therapy , *PROTEIN stability - Abstract
• Drug resistance towards chemotherapy and molecularly targeted therapies remains a great challenge in cancer treatments. • Deubiquitinating enzymes (DUBs) regulate protein stability and are extensively involved in many biological processes. • Dysregulations of DUBs frequently play important roles in drug resistance. • Therapies that combine current anti-cancer drugs and DUB inhibitors may provide new opportunities for drug resistance. Drug resistance to chemotherapy and molecularly targeted therapies is a current challenge in cancer treatments. The underlying mechanisms of resistance to cytotoxic chemotherapeutics and to drugs that target a specific molecule are not understood completely. In recent years, emerging evidence has frequently suggested that the dysregulation of deubiquitinating enzymes (DUBs) plays important roles in the development of drug resistance. We focus on the molecular mechanisms through which DUBs enable cancer cells to escape cell death and survive when exposed to a variety of anti-cancer drugs. Furthermore, this review summarizes the potential application of DUB inhibitors in combination therapies to overcome drug resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Progress and perspective of organoid technology in cancer-related translational medicine.
- Author
-
Lin, Yusheng, Jiang, Li, He, Qiaojun, Yuan, Meng, and Cao, Ji
- Subjects
- *
TRANSLATIONAL research , *CELL culture , *GENOME editing , *HIGH throughput screening (Drug development) , *INDIVIDUALIZED medicine - Abstract
Organoids are in vitro simplified and miniature microcosms of internal organs, which have aroused great interest in tissue development, multiple disease models, clinical diagnosis, as well as high-throughput drug screening and personalized medicine and so on. The success of physiology-related organoid culture has greatly advanced the translational medicine research in the field of cancer treatment, which was once troubled by the inconsistency between two-dimensional (2D) cell culture and in vivo studies. Especially in recent years, the success rate of establish an organoid has been greatly improved, and the types of organoids have been gradually enriched. Moreover, the utilizing of some the cutting-edge technologies, including gene editing technology such as CRISPR-Cas9, the scope of application of organoid is broadened. In this review, we discuss the latest progress and applications of organoids, and also outline the potential challenges of organoids for future improvement. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Targeting the Wnt/β-catenin signal pathway for the treatment of gastrointestinal cancer: Potential for advancement.
- Author
-
Jin, Xizhi, Wang, Sijie, Luo, Lihua, Yan, Fangjie, and He, Qiaojun
- Abstract
[Display omitted] Gastrointestinal cancers (GICs) are highly prevalent cancers that threaten human health worldwide. The Wnt/β-catenin signaling pathway has been reported to play a pivotal role in the carcinogenesis of GICs. Numerous interventions targeting the Wnt/β-catenin signaling in GICs are currently being tested in clinical trials with promising results. Unfortunately, there are no clinically approved drugs that effectively target this pathway. This comprehensive review aims to evaluate the impact of clinical therapies targeting the Wnt/β-catenin signaling pathway in GICs. By integrating data from bioinformatics databases and recent literature from the past five years, we examine the heterogeneous expression and regulatory mechanisms of Wnt/β-catenin pathway genes and proteins in GICs. Specifically, we focus on expression patterns, mutation frequencies, and clinical prognoses to understand their implications for treatment strategies. Additionally, we discuss recent clinical trial efforts targeting this pathway. Understanding the inhibitors currently under clinical investigation may help optimize foundational research and clinical strategies. We hope that elucidating the current status of precision therapeutic stratification for patients targeting the Wnt/β-catenin pathway will guide future innovations in precision medicine for GICs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Cediranib enhances the transcription of MHC-I by upregulating IRF-1.
- Author
-
Zhang, Jie, Guo, Hongjie, Wang, Longsheng, Zheng, Mingming, Kong, Shijia, Wu, Honghai, Zhao, Lin, Zhao, Qiong, Yang, Xiaochun, He, Qiaojun, Chen, Xi, Ding, Ling, and Yang, Bo
- Subjects
- *
T cells , *CYTOTOXIC T cells , *KILLER cells , *INTERFERON regulatory factors , *NON-small-cell lung carcinoma , *MAJOR histocompatibility complex , *T cell receptors , *PROTEIN stability - Abstract
[Display omitted] Diminished or lost Major Histocompatibility Complex class I (MHC-I) expression is frequently observed in tumors, which obstructs the immune recognition of tumor cells by cytotoxic T cells. Restoring MHC-I expression by promoting its transcription and improving protein stability have been promising strategies for reestablishing anti-tumor immune responses. Here, through cell-based screening models, we found that cediranib significantly upregulated MHC-I expression in tumor cells. This finding was confirmed in various non-small cell lung cancer (NSCLC) cell lines and primary patient-derived lung cancer cells. Furthermore, we discovered cediranib achieved MHC-I upregulation through transcriptional regulation. interferon regulatory factor 1 (IRF-1) was required for cediranib induced MHC-I transcription and the absence of IRF-1 eliminated this effect. Continuing our research, we found cediranib triggered STAT1 phosphorylation and promoted IRF-1 transcription subsequently, thus enhancing downstream MHC-I transcription. In vivo study, we further confirmed that cediranib increased MHC-I expression, enhanced CD8+ T cell infiltration, and improved the efficacy of anti-PD-L1 therapy. Collectively, our study demonstrated that cediranib could elevate MHC-I expression and enhance responsiveness to immune therapy, thereby providing a theoretical foundation for its potential clinical trials in combination with immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Synthesis and anticancer activity of a novel class of flavonoids: 2,4-Diarylchromane[4,3-d]-Δ1,9b-1,2,3-thiadiazolines
- Author
-
Ying, Huazhou, Hu, Yongzhou, He, Qiaojun, Li, Runping, and Yang, Bo
- Subjects
- *
ANTINEOPLASTIC agents , *FLAVONOIDS , *RING formation (Chemistry) , *CANCER cells , *DNA - Abstract
Abstract: A series of 2,4-diarylchromane[4,3-d]-Δ1,9b-1,2,3-thiadiazolines have been synthesized by cyclization of corresponding 2-arylchroman-4-one-arylhydrazones with SOCl2 then treated with alcohol. All the compounds have been tested for their antiproliferative activity in vitro against six human tumor cell lines, and the highly potent derivative 11a exhibited in vivo inhibitory effect on tumor growth. Mechanism research indicated that it is due to 11a that induces DNA fragmentation. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
38. Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: Design, synthesis, and biological evaluation
- Author
-
Liu, Tao, Xu, Zhongmiao, He, Qiaojun, Chen, Yanhong, Yang, Bo, and Hu, Yongzhou
- Subjects
- *
FLAVONOIDS , *APOPTOSIS , *CYCLIN-dependent kinases , *CYTOMETRY - Abstract
Abstract: A novel series of nitrogen-containing flavonoids 5a–l, 6a,b, and 7a,b were designed and synthesized as cyclin-dependent kinases (CDKs) inhibitors. The representative compounds 5a, 5b, 5e, and 5g showed potent CDK1/Cyclin B inhibitory activities. All compounds displayed a significant growth inhibitory action in vitro against Bel-7402, PC-3, ECA-109, A-549, HL-60, and MCF-7 cancer cell lines. Flow cytometry analysis showed that 5b induced apoptosis in PC-3 cells. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
39. Effects of prepubertal exposure to forchlorfenuron through prenatal and postnatal gavage administration in developing Sprague-Dawley rats.
- Author
-
Zhu, Difeng, Ping, Li, Shen, Xiaofei, Hong, Yawen, Weng, Qinjie, He, Qiaojun, Wang, Jiajia, and Wang, Jincheng
- Subjects
- *
SPRAGUE Dawley rats , *ESTRUS , *TUBE feeding , *BLOOD urea nitrogen , *PLANT regulators , *ESTROGEN receptors - Abstract
Forchlorfenuron (CPPU), a plant growth regulator, is widely used in agriculture. However, its long-term exposure effects on humans, especially neonates, remain unclear. Therefore, we investigated the developmental toxicity of prenatal and postnatal gavage administration of CPPU in rats. Pregnant Sprague-Dawley rats were administered 300 mg/kg/day CPPU by gavage from day 6 of gestation to the cessation of nursing. During weaning, rat offspring were administered 0, 30, 100, or 300 mg/kg/day CPPU for 4 weeks, followed by a 4-week CPPU-free recovery period. There were no significant differences in clinical symptoms, body weight, development indicators, serum biochemical parameters, sex hormone levels, sperm motility, relative organ weights, and histopathological changes among the 0–100 mg/kg/day CPPU groups. In the 300 mg/kg/day CPPU group, female rats exhibited decreased body weight, earlier time of vaginal opening (VO) and first estrus time (FE), elevated estradiol and blood urea nitrogen (BUN) levels, and upregulation of estrogen receptor 1 gene expression, whereas male rats only exhibited increases in serum BUN, creatinine, and glucose levels. Most changes were reversed after the recovery period. Furthermore, the endometrial epithelial height was significantly increased in female rats despite the absence of significant changes in uterine wall thickness and endometrial glands. Thus, CPPU may promote estradiol secretion, resulting in altered VO and FE and adverse effects in prepubertal female rats. These findings may be applied for risk assessment following CPPU exposure in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
40. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
- Author
-
Zhu, Haiying, Du, Chengyong, Yuan, Meng, Fu, Peifen, He, Qiaojun, Yang, Bo, and Cao, Ji
- Subjects
- *
PROGRAMMED cell death 1 receptors , *TRIPLE-negative breast cancer , *TUMOR microenvironment , *PROGRAMMED death-ligand 1 , *ADJUVANT treatment of cancer - Abstract
• Triple negative breast cancer (TNBC) has high degree of immune cell infiltration. • Anti-programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) antibodies monotherapy has mild respond. • Combination immunotherapy for TNBC has received extensive attention. • Propose multiple strategies to overcome bottleneck in TNBC immunotherapy treatment. Despite extensive research into adjuvant and neoadjuvant chemotherapy, triple-negative breast cancer (TNBC) remains a common breast cancer (BC) subtype with poor prognosis. Given that it has higher immune cell infiltration, theoretically, it should be a protagonist of potential BC immunotherapies. However, only mild responses have been observed in monotherapy with anti-programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) antibodies. In this review, we reappraise PD-1/PD-L1 inhibitor combination immunotherapy and effective experimental compounds, focusing the level of PD-L1 expression, neoantigens, abnormal signaling pathways, and tumor microenvironment signatures, to provide guidance for future clinical trials based on the molecular mechanisms involved. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
41. The posttranslational modifications of Hippo-YAP pathway in cancer.
- Author
-
Yan, Fangjie, Qian, Meijia, He, Qiaojun, Zhu, Hong, and Yang, Bo
- Subjects
- *
SMALL molecules , *PROTEIN stability , *POST-translational modification , *DRUG resistance in cancer cells , *CANCER treatment , *CANCER , *KINASES - Abstract
Yes-associated protein (YAP) is a key effector of the Hippo pathway and is frequently dysregulated in aggressive human cancers. Aberrant YAP activation has emerged as an important driver of tumorigenesis, chemoresistance and metastasis. Since posttranslational modifications (PTMs) are pivotal modifiers that determine protein activation or subcellular localization, the malfunction of YAP due to dysregulated PTMs has been linked to various cancers. Collectively, although YAP has long been considered an "undruggable" transcription cofactor, its PTMs may be its "Achilles' heel". To provide theoretical support for developing small molecule inhibitors based on PTMs, in this review article, we summarize the current understanding of the impact of PTMs in regulating the Hippo-YAP pathway and further discuss potential therapeutic intervention. In our review, we summarize the known posttranslational modifications (PTMs) of YAP that dictate its protein stability, transcriptional activity and subcellular localization at different stages. Here, we clearly summarize the specific enzymes and sites involved in YAP PTMs and place additional focus on the consequences of PTM-modulated YAP activity and translocation. PTMs of YAP play fundamental roles in controlling the protein abundance and function. Therefore, interfering with PTMs of YAP may contribute to solving the "undruggable" problem in YAP inhibition, thus providing new approaches for YAP-based cancer therapy. Future studies that target corresponding PTM-related kinases/enzymes will provide new strategies for cancer therapy, particularly in tumors with YAP dysregulation. • YAP is a transcriptional cofactor and generally dysregulated in cancers. • Posttranslational modifications dictate diverse aspects of YAP activity. • Targeting PTMs may be an effective strategy to inhibit YAP-mediated tumorigenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
42. Targeting post-translational modification of transcription factors as cancer therapy.
- Author
-
Qian, Meijia, Yan, Fangjie, Yuan, Tao, Yang, Bo, He, Qiaojun, and Zhu, Hong
- Subjects
- *
TRANSCRIPTION factors , *CANCER treatment , *GENE regulatory networks , *GENE expression , *NUCLEAR receptors (Biochemistry) - Abstract
• Transcription factors are generally dysregulated in tumors. • Most oncogenic transcription factors are considered as "undruggable" targets. • Post-translational modifications dictate diverse aspects of transcription factors. • Agents that target transcription factors PTMs exert potent anti-tumor activities. Dysregulated transcription factors (TFs) fuel aberrant gene expression networks, resulting in cell overproliferation, migration, and immunosuppression. Given that TFs are regarded to have vital roles in tumors, various approaches are exploited to modulate their activities. Nevertheless, except for some ligand-binding nuclear receptors, most TFs are still considered 'undruggable' targets. Responding to extra- or intracellular stimuli, TFs are decorated with an array of post-translational modifications (PTMs) to regulate their subcellular localizations, protein–protein/DNA interactions, and stability. These PTMs orchestrate the multiple functions of TFs, thus offering numerous potential targets. In this review, we systematically review emerging concepts and effective agents in PTMs-associated TF-targeting, which could provide paradigms for cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
43. Advances in differentiation therapy for osteosarcoma.
- Author
-
Chen, Yingqian, Cao, Ji, Zhang, Ning, Yang, Bo, He, Qiaojun, Shao, Xuejing, and Ying, Meidan
- Subjects
- *
CELL differentiation , *OSTEOSARCOMA - Abstract
• Osteosarcoma is a disease resulting from osteogenic differentiation defects. • Differentiation therapy for osteosarcoma has received extensive attention. • Various agents have been shown to induce terminal differentiation in osteosarcoma. • The exploration of new inducers and biomarkers is the way forward. Differentiation therapy involves the use of agents that can induce differentiation in cancer cells, with the irreversible loss of tumour phenotype. The application of differentiation therapy in osteosarcoma has made progress because of a better understanding of the potential links between differentiation defects and tumorigenesis. Here, we review recent studies on differentiation therapy for osteosarcoma, describing a variety of differentiation inducers. By highlighting these examples of drug-induced osteosarcoma cell differentiation, we can acquire unique insights into not only osteosarcoma treatment, but also novel approaches to transform differentiating drugs into more effective therapies for other solid tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
44. Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer.
- Author
-
Zhao, Lin, Chen, Xi, Wu, Honghai, He, Qiaojun, Ding, Ling, and Yang, Bo
- Subjects
- *
CYTOTOXIC T cells , *PROGRAMMED cell death 1 receptors , *OVARIAN cancer , *PROGRAMMED death-ligand 1 , *TUMOR antigens , *CELL death , *T cells - Abstract
[Display omitted] Anti-programmed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) antibodies have developed rapidly but exhibited modest activity in ovarian cancer (OC), achieving a clinical response rate ranging from 5.9% to 19%. Current evidence indicate that the establishment of an integrated cancer-immunity cycle is a prerequisite for anti-PD-1/PD-L1 antibodies. Any impairment in this cycle, including lack of cancer antigens release, impaired antigen-presenting, decreased T cell priming and activation, less T cells that are trafficked or infiltrated in tumor microenvironment (TME), and low tumor recognition and killings, will lead to decreased infiltrated cytotoxic T cells to tumor bed and treatment failure. Therefore, combinatorial strategies aiming to modify cancer-immunity cycle and reprogram tumor immune microenvironment are of great interest. By far, various strategies have been studied to enhance responsiveness to PD-1/PD-L1 inhibitors in OC. Platinum-based chemotherapy increases neoantigens release; poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) improve the function of antigen-presenting cells and promote the trafficking of T cells into tumors; epigenetic drugs help to complete the immune cycle by affecting multiple steps; immunotherapies like anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies reactivate T cells, and other treatment strategies like radiotherapy helps to increase the expression of tumor antigens. In this review, we will summarize the preclinical studies by analyzing their contribution in modifying the cancer immunity cycle and remodeling tumor environment, and we will also summarize recent progress in clinical trials and discuss some perspectives to improve these treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Crizotinib induces pulmonary toxicity by blocking autophagy flux in alveolar epithelial cells.
- Author
-
Zhang, Yuanteng, Gao, Zizheng, Pan, Zezheng, Fu, Huangxi, Jiang, Feng, Yan, Hao, Yang, Bo, He, Qiaojun, Luo, Peihua, Xu, Zhifei, and Yang, Xiaochun
- Subjects
- *
CRIZOTINIB , *EPITHELIAL cells , *ANAPLASTIC lymphoma kinase , *NON-small-cell lung carcinoma , *INTERSTITIAL lung diseases , *AUTOPHAGY - Abstract
[Display omitted] Crizotinib is the first-line drug for advanced non-small cell lung cancer with the abnormal expression of anaplastic lymphoma kinase gene. Severe, life-threatening, or fatal interstitial lung disease/pneumonia has been reported in patients treated with crizotinib. The clinical benefit of crizotinib is limited by its pulmonary toxicity, but the underlying mechanisms have not been adequately studied, and protective strategies are relatively scarce. Here, we established an in vivo mouse model in which crizotinib was continuously administered to C57BL/6 at 100 mg/kg/day for 6 weeks and verified that crizotinib induced interstitial lung disease in vivo , which was consistent with the clinical observations. We further treated BEAS-2B and TC-1 cells, the alveolar epithelial cell lines, with crizotinib and found the increased apoptosis rate. We proved that crizotinib-blocked autophagic flux caused apoptosis of the alveolar epithelial cells and then promoted the recruitment of immune cells, suggesting that limited autophagy activity was the key reason for pulmonary injury and inflammation caused by crizotinib. Subsequently, we found that metformin could reduce the macrophage recruitment and pulmonary fibrosis by recovering the autophagy flux, thereby ameliorating impaired lung function caused by crizotinib. In conclusion, our study revealed the mechanism of crizotinib-induced apoptosis of alveolar epithelial cells and activation of inflammation during the onset of pulmonary toxicity and provided a promising therapeutic strategy for the treatment of crizotinib-induced pulmonary toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Bisdemethoxycurcumin protects against renal fibrosis via activation of fibroblast apoptosis.
- Author
-
Jin, Fuquan, Jin, Ying, Du, Jiangxia, Jiang, Liyu, Zhang, Ying, Zhao, Ziying, Yang, Bo, Luo, Peihua, and He, Qiaojun
- Subjects
- *
RENAL fibrosis , *FIBROBLASTS , *APOPTOSIS , *KIDNEY diseases , *NATURAL products - Abstract
Abstract Renal fibrosis is the common final outcome of nearly all progressive chronic kidney diseases (CKD) that eventually develop into end-stage renal failure, which threatens the lives of patients. Currently, there are no effective drugs for the treatment of renal fibrosis. However, studies have shown that certain plant natural products have a fibrosis-alleviating effect. Thus, we have screened a large number of natural products for their ability to protect against renal fibrosis and found that bisdemethoxycurcumin has a good therapeutic effect in renal fibrosis according to the data obtained in a mouse model of unilateral ureteral obstruction (UUO). The results indicate that bisdemethoxycurcumin can efficiently attenuate renal fibrosis induced by UUO. Additional studies of the bisdemethoxycurcumin mechanism of action in the treatment of renal fibrosis demonstrated that the therapeutic effect of bisdemethoxycurcumin is mediated by the specific induction of fibroblast apoptosis at a concentration of 20 μM. bisdemethoxycurcumin can efficiently protect against renal fibrosis both in vitro and in vivo. This discovery will provide new ideas for renal fibrosis treatment in clinics and a new direction for the development of effective drug therapy of renal fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
47. A practical "preTACs-cytoblot" platform accelerates the streamlined development of PROTAC-based protein degraders.
- Author
-
Rao, Zijian, Li, Kailin, Hong, Ju, Chen, Danni, Ding, Baoli, Jiang, Li, Qi, Xuxin, Hu, Jiawen, Yang, Bo, He, Qiaojun, Dong, Xiaowu, Cao, Ji, and Zhu, Cheng-Liang
- Subjects
- *
DRUG discovery , *AZIDO group , *CYCLIN-dependent kinases , *PROTEINS , *ALKENES , *PROTEOLYSIS - Abstract
With the growing importance of PROTAC-mediated protein degradation in drug discovery, robust synthetic methodologies and rapid screening assays are urgently needed. By harnessing the improved alkene hydroazidation reaction, we developed a novel strategy to introduce azido groups into the linker-E3 ligand conjugates and effectively created a range of prepacked terminal azide-labeled "preTACs" as PROTAC toolkit building blocks. Moreover, we demonstrated that preTACs are ready to conjugate to ligands targeting a protein of interest to generate libraries of chimeric degraders, which are subsequently screened for effective protein degradation directly from cultured cells with a cytoblot assay. Our study exemplifies that this practical "preTACs-cytoblot" platform allows efficient PROTAC assembly and rapid activity assessments. It may help industrial and academic investigators to accelerate their streamlined development of PROTAC-based protein degraders. [Display omitted] • A practical preTACs-Cytoblot platform is reported to streamline the PROTAC discovery. • Alkene hydroazidation is a useful method to synthesize the preTAC building blocks. • Improved methods to efficiently conjugate preTACs to the ligand of a target protein. • The Cytoblot assay was used to assess PROTAC activity directly from cells rapidly. • A potent CDK12 degrader V7 was identified with cell-selective antiproliferation activity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Corrigendum to "Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics" [Eur. J. Pharmacol. 926 (2022) 175035].
- Author
-
Wu, Qian, Zhang, Mingyang, Wen, Yuanmei, He, Peihao, He, Qiaojun, Yang, Bo, Jiang, Li, Yuan, Meng, and Cao, Ji
- Subjects
- *
DISULFIRAM , *ALCOHOLISM , *THERAPEUTICS , *DRUGS - Published
- 2023
- Full Text
- View/download PDF
49. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome.
- Author
-
Chen, Min, Chen, Jian, Peng, Xueming, Xu, Zhifei, Shao, Jinjin, Zhu, Yuanrun, Li, Guanqun, Zhu, Hong, Yang, Bo, Luo, Peihua, and He, Qiaojun
- Subjects
- *
KERATINOCYTES , *HAND-foot syndrome , *APOPTOSIS , *APOPTOSIS inhibition , *ACANTHOLYSIS , *GENETICS - Abstract
Capecitabine, as the first-line treatment for multiple tumor types, has a serious drawback of hand-foot-syndrome (HFS) that limits its clinical use. However, the pathophysiology and mechanism of capecitabine-induced HFS is rarely known. Here we built the experimental mouse model of HFS induced by capecitabine at first and it was shown that 3 of 6 mice appeared HFS in the 5th day and 5 mice occurred HFS in the 30th day. The corneous layer was reduced in capecitabine-induced HFS in vivo. Moreover, we found that capecitabine could significantly induce keratinocytes cells death in vitro through activated apoptosis pathway and decreased mitochondrial membrane potential. In conclusion, these results suggested that HFS of capecitabine may be developed from reduction of corneous layer through stimulation of intracellular mitochondrial dysfunction following activation of caspase-dependent apoptosis pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
50. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends.
- Author
-
Zhang, Yuanteng, Gao, Zizheng, Jiang, Feng, Yan, Hao, Yang, Bo, He, Qiaojun, Luo, Peihua, Xu, Zhifei, and Yang, Xiaochun
- Subjects
- *
ADULT respiratory distress syndrome , *PULMONARY edema - Abstract
[Display omitted] Acute respiratory distress syndrome (ARDS) is characterized by noncardiogenic pulmonary edema. It has a high mortality rate and lacks effective pharmacotherapy. With the outbreak of COVID-19 worldwide, the mortality of ARDS has increased correspondingly, which makes it urgent to find effective targets and strategies for the treatment of ARDS. Recent clinical trials of Janus kinase (JAK) inhibitors in treating COVID-19-induced ARDS have shown a positive outcome, which makes the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway a potential therapeutic target for treating ARDS. Here, we review the complex cause of ARDS, the molecular JAK/STAT pathway involved in ARDS pathology, and the progress that has been made in strategies targeting JAK/STAT to treat ARDS. Specifically, JAK/STAT signaling directly participates in the progression of ARDS or colludes with other pathways to aggravate ARDS. We summarize JAK and STAT inhibitors with ARDS treatment benefits, including inhibitors in clinical trials and preclinical studies and natural products, and discuss the side effects of the current JAK inhibitors to reveal future trends in the design of JAK inhibitors, which will help to develop effective treatment strategies for ARDS in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.